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Chemotherapy agents have little or no specificity over cancer cells, resulting in low 
therapeutic concentrations at the tumor site (a consequence of a broad systemic distribution), 
and severe side effects. With the aim of avoiding cancer therapy failure, several approaches 
such as design of new anticancer drugs, chemical engin ering of conventional drugs and 
development of drug delivery systems have been proposed. The objective is to enhance drug 
localization at the tumor region (by controlling its biodistribution profile) and, therefore, to 
increase the anti-tumor efficacy (even in multi-drug resistant tumors), while reducing 
systemic side effects. One of the most promising approaches to the problem is the 
development of drug nanocarriers based on the polymer poly(ε-caprolactone). In this review 
we will focus our attention on these polymeric colloids, particularly on the most significant 
characteristics and formulation procedures, and on their use as nanoplatforms for the delivery 
of chemotherapy agents to the tumor site. Furthermore, the most recent in vitro and in vivo 
investigations on the subject are extensively reviewed. 
 
KEYWORDS: Anti-tumor Drug, Cancer, Controlled Release, Drug Carriers, Drug Delivery, 
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INTRODUCCION  
Cancer therapy strategies are currently focussed on surgery, chemotherapy, radiotherapy, 
immunotherapy and hormonal therapy. These conventional strategies are limited by the 
accessibility to the tumor and the lack of selectivity towards tumor cells, the spread of cancer 
cells throughout the body, and the risk of operating on a vital organ. Regarding cancer 
chemotherapy, treatment failure is frequently encoutered even in the most sensitive cancers 
to chemotherapy agents1. Several reasons have been pointed out for chemotherapy failure: i) 
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the physicochemical properties of many drugs, e.g., hydrophobicity, promotes the 
unsuccessful localization at the cancer site; i ) the unfavorable pharmacokinetics (rapid 
clearance and rapid in vivo degradation) determine the need of higher doses and rigorous 
treatment schedules to obtain a therapeutic effect; iii ) the relative poor selectivity of 
chemotherapy agents for targeted tumor cells; iv) the large biodistribution and non-intended 
extravasation with severe side effects in non-targeted sites; and v) the susceptibility to induce 
drug resistance2-4. Cancer physiology is also responsible for the chemotherapy failure, mainly 
because of the absence of a non-functional lymphatic system that allows drug escaping out of 
the tumor, and due to a very high hydrostatic pressure gradient inside the tumor that difficult a 
uniform drug diffusion inside the tumor5,6. 
The association of anti-tumor drugs to colloidal delivery systems in cancer treatment has 
been proposed to improve their efficacy and to reduc  their associated toxicity. This strategy 
could allow obtaining a specific accumulation at the tumor site, an improvement of the 
pharmacokinetic profile, a prolongation of the exposure of the tumor cells to these active 
agents and a minimization of the severe side effects2,7. 
With this aim, it have been established that a suitable anti-tumor drug delivery system 
should have the following properties: i) small size (≤ 500 nm) to allow a large biodistribution 
and an adequate perfusion at the target site; ii ) the ability to deliver therapeutic drug 
quantities, without overloading the organism with foreign material; iii ) physical stability and 
low drug leakage problems under storage and in vivo; iv) controlled drug release rates 
exclusively at the targeted tumor; and v) maximum biocompatibility and biodegradability 
(with very low toxicity of breakdown products), and minimal antigenicity2,8. These drug 
carriers are frequently based on vesicular (liposomes and niosomes) and polymeric systems. 
Special approaches such as surface-functionalization (e.g., with specific ligands to tumor 
cells) and engineering of stimuli-sensitive materials, could enhance the biodistribution profile 
of loaded drugs and, thus, resulted in a more effici nt tumor therapy2,6,9. 
One of the most promising materials for the design of nanocarriers loaded with 
chemotherapy agents is the biodegradable polymer poly(ε-caprolactone) (PCL).  This 
aliphatic polyester is very suitable for controlled drug delivery due to its high permeability to 
many drugs and non-toxicity, its exceptional ability to form blends with other polymers, and 
its very low degradation rate (compared to other well known drug carriers, such as poly(D,L-
lactide-co-glycolide) (PLGA)10. Thus, it is of great interest to review the most significant 
characteristics and preparation procedures of PCL, giving special attention to its use in drug 
delivery to tumors. This paper will also detail the most important in vitro and in vivo 
investigations on the subject. 
 
MAJOR PROPERTIES OF POLY( ε-CAPROLACTONE) FOR DRUG DELIVERY 
ε-caprolactone (ε-CL) is a monomer widely used in the preparation of different polymers, 
including poly(ε-caprolactone) (PCL), by opening the with nucleophiles, e.g., water and 
alcohol. PCL is a synthetic aliphatic polyester, biodegradable, biocompatible and highly 
hydrophobic. It is typically prepared by ring-opening polymerization of ε-CL (figure 1). The 
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average molecular weight (Mw) of PCL may vary from 10000 to 42500 Da. PCL is graded 
according to this Mw. PCL is soluble at room temperature in chloroform, dichloromethane, 
carbon tetrachloride, benzene, toluene, cyclohexanone and 2-nitropropane. It has a low 
solubility in acetone, 2-butanone, ethyl acetate, and it is insoluble in alcohol, petroleum, ether 
and diethyl ether11,12. 









This crystalline polymer has been widely utilized in numerous biomedical applications 
such as design of sustained-release drug delivery systems, because of its slow degradation 
rate, high drug permeability and non-toxicity. It is also used with very promising results in 
tissue-engineering scaffolds11,12. The combination of PCL with other polymers, such as PLGA 
or poly(D,L-lactide) (PLA), is widely used to obtain copolymers with higher stress crack 
resistance, dyeability and adhesion properties. The formulation of PCL-based copolymers can 
also allow manipulating the drug release rate from this systems13,10. 
In vivo studies have suggested the great biocompatibility, cytocompatibility and non-
toxicity of PCL, with only non-significant inflammation reactions as a consequence of the 
high local concentrations assayed in these studies14-16. The degradation of PCL is an 
autocatalyzed process, whereby the generated carboxylic groups catalyze an autohydrolysis 
reaction, i.e. the cleavage of additional ester groups14. In vivo degradation is also clearly 
determined by phagocytosis10. 
 
SYNTHESIS PROCEDURES FOR THE FORMULATION OF DRUG-LO ADED 
POLY(ε-CAPROLACTONE) CARRIERS 
Poly(ε-caprolactone) (PCL) particles can be prepared either by the polymer alone or by 
using PCL copolymers or blends. Several methods have been reported in the literature for the 
preparation of drug-entrapped PCL particles, including interfacial disposition, interfacial 
polymerization, solvent evaporation, desolvation of macromolecules, emulsion 
polymerization in continuous aqueous phase or in continuous organic phase, or 
electrohydrodynamic atomization, to cite just a few10. 
With respect to drug-loaded PCL microparticles, the most important preparation methods 
are: 
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i) The o/w emulsion solvent extraction/evaporation method, where typically the required 
amount of polymer and drug are dissolved in an organic phase which is emulsified under 
mechanical stirring with a poly(vinyl alcohol) (PVA) solution to form an o/w emulsion17. 
ii ) The w/o/w emulsion solvent evaporation technique. An aqueous solution of the drug is 
emulsified with PCL in dichloromethane. Then, the rsulting w/o emulsion is again 
emulsified under mechanical stirring with water contai ing PVA as an emulsifier18. 
iii ) The spray drying technique. An organic solution of the drug and the polymer is made in a 
mixture of dichloromethane and chloroform (1:1). This organic solution is finally sprayed 
through a nozzle in a spray-drier19. 
iv) The solution-enhanced dispersion method. This approach overcomes the problems 
associated to the use of organic solvents (e.g., toxici y). It is based on the use of supercritical 
fluids like carbon dioxide20. 
v) The hot melt technique. This synthesis method is frequently used for the preparation of 
polymeric microparticles with low melting point materials, such as PCL. The molten polymer 
is dispersed in a suitable dispersion medium and slowly cooled to form the microparticles21. 
Regarding the formulation of PCL nanoparticles, the int rfacial polymer disposition and 
the dialysis methods are frequently used10,22. Interfacial polymer disposition is based on the 
displacement of a water-miscible semi-polar solvent from a lipophilic solution. Briefly, the 
polymer is dissolved in an organic solvent (e.g., acetone). A mixture of phospholipids is 
prepared in the same organic solvent by heating to near the boiling point. After mixing both 
solutions, the resulting organic phase is mixed with a benzyl benzoate-drug solution and it is 
poured under stirring to an aqueous poloxamer solution. A colloidal nanoparticle suspension 
is immediately obtained and the organic solvent is removed under reduced pressure. 
Regarding the dialysis method, the polymer is dissolved in an organic solvent (usually, 
dimethylformamide) and the drug is added to this solution under stirring at room temperature. 
After removing the organic solvent, dialysis is done using a cellulose membrane bag during 
24 h. Subsequently, the micellar solution is collected from the bag, sonicated and centrifuged 
to eliminate the unloaded drug and the macroaggregates. Finally, lyophilization is carried out 
for 2 days, obtaining the polymeric nanoparticles. 
 
The preparation procedures that are used for the formulation of PCL copolymers are 
usually based of the previously commented synthesis methods for the preparation of PCL 
micro- and nano-particles10. The synthesis routines that are mainly followed are the 
nanoprecipitacion method, the interfacial dispositin technique, the solvent displacement 
process and the double emulsion pressure homogenizatio  technique10,23,24. Following these 
preparation methods, it have been synthesized poly(eth lene oxide) (PEO)–poly(propylene 
oxide) (PPO)–poly(ethylene oxide)–PCL [PEO-PPO-PEO)–PCL], PEO-PCL25, methoxy 
poly(ethylene glycol) (MePEG)–PCL26, PCL–PEG–PCL 27,28 and self-assembled amphiphilic 
PCL grafted PVA (PCL-g-PVA) copolymers29. PCL nanoparticles have also been surface-
functionalized with chitosan and poly-L-lysine30. 
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APPLICATIONS OF POLY( ε-CAPROLACTONE) AS DRUG DELIVERY SYSTEMS 
FOR CANCER TREATMENT 
Biodegradable poly(ε-caprolactone) (PCL) particles are one of the most promising drug 
delivery systems. Various categories of drugs have be n encapsulated in PCL micro- and 
nano-particles for their effective delivery. The results that have been obtained in vitro and in 
vivo with anti-tumor drug-loaded PCL particles have determined their potential in cancer 
treatment. PCL colloids loaded with anticancer drugs (e.g., 5-fluorouracil, doxorubicin, 
paclitaxel, etc.) have shown enhanced anti-tumor activity as a consequence of a higher 
therapeutic efficacy and a reduced systemic toxicity2,10. The development of multi-drug 
resistances associated to long-term chemotherapy can also be minimized31 or overcome32. 
Tamoxifen-loaded PCL nanoparticles were proposed for the treatment of breast cancer31. 
The preparation procedure is based on a solvent diffusion technique which involved the 
addition under stirring of a drug-polymer acetone solution into a pluronic F-68 aqueous 
solution. Cell internalization studies in MCF-7 breast cancer cells employing fluorescent 
nanoparticles showed that after 1 hour of incubation, a high concentration of nanoparticles 
was found in the cytoplasm and in the perinuclear rgion, suggesting a great cell penetration 
(higher than in the case of the free drug) by a non-specific endocytosis33. Even more, surface 
functionalization with PEO significantly increased drug accumulation within tumor as well as 
extended their presence in the systemic circulation34. It was determined that the higher 
concentration of nanoparticles delivered to the tumor would result in net intracellular drug 
concentration and, hence, greater efficacy of the treatment. Hence, this tamoxifen-loaded 
nanocarrier was supposed to be very useful in effective drug delivery to breast cancer, which 
may be especially interesting to minimize the adverse side effects (e.g., subsequent 
endometrial cancer) and the development of resistances associated to long-term prophylactic 
therapy in high-risk and postmenopausal women. 
A number of 5-fluorouracil (5-FU) delivery systems based on PCL have been studied for 
cancer treatment35-37. Recently, PCL particles loaded with doxifluridine (5´-deoxy-5-
fluorouridine, 5´-DFUR) were prepared by ring-opening polymerization of ε-CL, using Sn(II) 
2-ethylhexanoate (Sn(Oct)2) as catalyst. This is a prodrug that is mostly converted to the 
active drug (5-FU) by the enzyme thymidine phosphorylase in tumor tissue30. Moreover, PCL 
colloids have been formulated for the enhancement of the bioavailability and in vivo stability 
of curcumin (a polyphenolic compound with anti-tumor activity) with very interesting 
results38. PCL particles have also been loaded with the anti-estrogen RU 58668 (a promising 
estrogen-dependent anticancer agent) (mean diameter ≈ 30 – 50 nm) and tested for cancer 
treatment. This formulation developed an intratumoral extravasation behavior and the slow 
drug release proved to be able to inhibit estrogen-induced transcription in human breast 
cancer cells39. 
One of the most interesting applications of PCL nanoparticles is as anti-tumor targeting 
systems in multi-drug resistance (MDR) tumors. As an example, a combination of paclitaxel 
(PTX) and C6-ceramide (CER, an apoptotic signalling molecule) in PCL nanoparticles (≈ 200 
nm) surface functionalized with PEO was used for overcoming MDR in ovarian cancer40. A 
single dose of PTX (20 mg/Kg) and CER (100 mg/kg)-loaded nanoparticle formulations to 
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subcutaneous sensitive (wild-type) and MDR-1 positive SKOV-3 human ovarian 
adenocarcinoma xenograft-bearing female Nu/Nu mice, induced a significant (P < 0.05) 
tumor growth suppression as compared to the administration of aqueous solutions of each 
molecule. For instance, in SKOV-3 wild-type model, more than 4.3-fold increase (P < 0.05) 
in tumor growth delay and 3.6-fold (P < 0.05) increase in tumor volume doubling time (DT) 
were observed when co-administering both types of nanoparticles as compared to untreated 
animals. Similarly, 3-fold increase (P < 0.05) in tumor growth delay and tumor volume DT 
was observed in the SKOV-3TR multi-drug resistance model. With respect to the toxicity, no 
significant differences were observed. Moreover, a paclitaxel/tamoxifen co-therapy based on 
PEO-PCL nanoparticles showed a decrease in the inhibitory concentration 50 (IC50) of PTX 
by 10-fold in SKOV-3 cells and by > 3-fold in SKOV-3TR cells, without any significant acute 
toxicity32. 
Depot-based PCL systems have been also proposed for cancer treatment with very 
promising results. As an example, a bleomycin depot based on PCL microparticles was 
evaluated in vivo in tumor-bearing mice. Interestingly, upon subcutaneous injection, the 
biodegradable depot-forming PCL microspheres controlled drug release and significantly 
suppressed the tumor growth kinetics compared to control41. An injectable PTX-polymer 
paste formulation based on a random copolymer of PLA and PCL with PEG, blended with 
MePEG was proposed for the treatment of prostate tumors. This PTX-loaded copolymer was 
administered intratumoraly into non-metastatic human prostate LNCaP tumor-bearing mice. 
The administration of this PTX-loaded paste induced a decrease in the serum prostate-specific 
antigen (PSA) levels and in the tumor volume in comparison to the blank paste. No significant 
toxicity but minor ulceration at the injection site was observed42. Finally, an injectable and in 
situ forming drug delivery system based on photocrosslinked poly(ε-caprolactone fumarate) 
networks loaded with tamoxifen citrate (TC) were evaluated against MCF-7 breast cancer cell 
line. The cytotoxicity assay showed that while this photocrosslinked network exhibited no 
significant cytotoxicity against MCF-7 cells, ≈ 60 % of the MCF-7 cells were killed after 
incubation with TC-loaded devices43. 
Furthermore, PCL micelles are emerging as effective drug carriers for hydrophobic 
photosensitizers in photodynamic therapy (PDT) and, even, as a potential dual carrier for the 
synergistic combination of PDT and chemotherapy for the treatment of cancer44. As an 
example, the photophysical and photochemical properties of protoporphyrin IX (PpIX)-loaded 
MePEG-b-PCL diblock copolymers (mean diameter ≈ 50 nm; loading efficiency ≈ 80 %) 
were compared to that of free PpIX. The cellular uptake of PpIX in RIF-1 cells using PpIX 
micelles was approximately two-fold higher than free PpIX. In vitro PDT results showed that 
the PpIX micelles have markedly increased photocytotoxicity over that achieved with free 
PpIX, by nearly an order of magnitude at the highest light dose used45. Micelles of 
MePEG750-b-oligo(ε-caprolactone)5 (MePEG750-b-OCL5) were loaded with the 
photosensitizer m-tetrahydroxyphenylchlorin (mTHPC) by a film hydration method. The 
cellular uptake of the drug-loaded micelles and their photocytotoxicity on human neck 
squamous carcinoma cells, in the absence and presence of lipase, were compared with free 
and liposomal mTHPC (Fospeg) formulations. This in vitro study revealed that the high 
loading capacity of the micelles, the high stability above the critical aggregation concentration 
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and the lipase-induced release of the photosensitizer make them very promising carriers for 
PDT in vivo46. 
As can be concluded, taking into account these veryinteresting results, the potential of 
PCL particles loaded with anticancer drugs is evident. However, the majority of the research 
efforts have been focussed on the use of copolymers due to their better drug loading and 
release properties, and to a more suitable biodegraation profile10. As an example, 
MePEG/PCL amphiphilic block copolymers (nanoparticle diameter ≈ 100 nm) proved to be 
able to encapsulate doxorubicin (DOX) in aqueous solutions. Confocal laser scanning 
microscopy (CLSM) demonstrated that drug-loaded micelles accumulated mostly in 
cytoplasm instead of cell nuclei, in contrast to free DOX. Furthermore, these drug-loaded 
particles exhibited time-delayed cytotoxicity in human MCF-7 breast cancer cells47. This 
biodegradable block copolymer has also been surface-functionalized with folic acid to target a 
folate-binding protein that is overexpressed on the surface of many tumor cells. With this aim, 
PTX-loaded folate-conjugated MePEG/PCL micelles (50 – 130 nm) were prepared by micelle 
formation in aqueous medium. The in vitro PTX release profile from the micelles showed no 
initial burst release but a clear sustained release. Int restingly, these PTX-loaded micelles 
proved much higher cytotoxicity for cancer cells (e.g., MCF-7 and HeLa cells) than 
MePEG/PCL micelles non-conjugated to folate. A confocal image analysis revealed that 
fluorescent PTX-loaded folate-conjugated micelles were endocytosed into MCF-7 cells 
through the interaction with overexpressed folate receptors on the surface of cancer cells48. 
Furthermore, PEG/PCL nanoparticles were prepared by a dialysis method and further surface-
functionalized with folate moieties (via a coupling reaction between the –OH groups of PEG 
and the –COOH group of folic acid) for the active targeting of 5-FU and PTX to tumors. It 
was observed an enhanced cytotoxicity of these drug-loaded nanoparticles against folate 
receptor expressing tumor cells49. MePEG/PCL nanoparticles loaded with taxol were prepa ed 
by a dialysis procedure26. This copolymer was also used in the vehiculization f 
geldanamycin. In this case, the pharmacokinetic profile of the drug was improved 
(enhancement in the AUC ≈ 72-fold) and this formulation exhibited a lower systemic 
toxicity50. Finally, MePEG/PCL nanoparticles loaded with cisplatin (entrapment efficiency ≥
75 %) have shown a significant less toxicity and an enhanced circulation time, compared to 
the free drug. Cisplatin release occurred in a sustained manner. In vitro cytotoxicity studies 
proved the efficacy of cisplatin-loaded nanoparticles against BGC823 and H22 cancer cell 
lines in a dose and time-dependent manner. Furthermor , compared with the free drug, 
cisplatin-loaded nanoparticles exhibited a superior anti-tumor effect by delaying tumor 
growth when delivered intratumorally (figure 2)51. 
Figure 2. Tumor volume of established H22 xenografts in ICR mice during therapy under 
different treatments. Mice were intratumorally treaed with different protocols on Day 0 
(tumor volume: 100 mm3). Saline: vehicle; empty np: empty nanoparticles; Ci platin: free 
cisplatin at a dose of 5, 10 and 20 mg/kg, respectiv ly; cisplatin-np: cisplatin-loaded 
nanoparticles in a saline solution at equivalent cisplatin doses of 5, 10 and 20 mg/kg, 
respectively. Data are presented as mean ± SD (n = 6). The difference between tumor 
volumes in the group of saline and cisplatin-loaded nanoparticles is highly significant (P < 
0.01). A significant difference (P < 0.05) is also observed between the group of free cisplatin 
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and cisplatin-loaded nanoparticles at the equivalent dose (*). Reprinted with permission from 
Ref. [51]. Copyright Elsevier (2008). 
 
 
Another PCL-based block copolymer was proposed for the delivery of vinblastine. By a 
modified o/w emulsion method PCL grafted dextran naoparticles were prepared, and an in 
vitro cytotoxicity assay in a breast cancer cell line (MCF-7) showed higher cancer cell 
mortality than the free drug52. This drug delivery system was also successfully assayed in 
vitro with coumarin-6 in a human gastric cancer cell line (SNU-638)53. 
Poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b PCL) and poly(ethylene oxide)-
block-poly(α-benzyl carboxylate ε-caprolactone) (PEO-b PBCL) micelles (< 90 nm) were 
engineered by a co-solvent evaporation technique as nanocarriers for the delivery of 
cucurbitacin I and B, which are inhibitors of the signal transducer and activator of 
transcription 3 (STAT3). It was determined that the anti-cancer and STAT3 inhibitory activity 
of the polymeric micellar cucurbitacins were comparable to the free drugs in vitro and in vivo 
in a B16-F10 melanoma cell line. Interestingly, theoxicity associated to cucurbitacin I and B 
was significantly reduced when these drugs were loaded into the nanoparticles54. 
A two-step nanoprecipitation method have been proposed for the synthesis of 
poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) block copolymer 
nanoparticles loaded with 10-hydroxycamptothecin (HCPT) (entrapment efficiency > 85 %). 
It was demonstrated that the HCPT-loaded nanoparticles developed a higher in vitro 
cytotoxicity, a superior in vivo anti-tumor activity and a remarkably different biodistribution 
in Sarcoma 180 (S180)-bearing mice than the free drug55. In addition, PCL-PEG-PCL 
nanoparticles were used as carriers for the water-insoluble drug oridonin in liver cancer 
treatment. This amphiphilic block copolymer (≈ 100 nm; entrapment efficiency ≈ 90 %) was 
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synthesized by an interfacial deposition method, in which the ring-opening polymerization of 
ε-CL was initiated by the –OH groups of PEG, with stannous octoate as catalyzer. The anti-
tumor activity of the oridonin-loaded PCL-PEO-PCL nanoparticles was evaluated by 
measuring changes in tumor volume, tumor weight and survival rates of mice with grafted 
hepatoma (H22). The results indicated that this anti-tumor drug delivery system prolonged the 
survival time of mice and exhibited a higher theraputic activity compared to free oridonin56. 
PCL-PEG-PCL nanoparticles were also used for the delivery of the biphenolic compound 
honokiol28. 
Poly(D,L-lactide-ran-ε-caprolactone)-poly(ethylene glycol)-poly(D,L-lactide-ran-ε-
caprolactone) tri-block copolymers loaded with 5-FU (drug loading > 90 %) were prepared by 
ring-opening polymerization of D,L-lactide and ε-CL in the presence of PEG, using Zn L-
lactate as initiator. The thermal behavior of the particles showed their potential as injectable 
drug-delivery devices: as the melting temperature approaches room temperature, a less porous 
inner structure is formed compared to the one under a higher melting temperature; this 
resulting in a slower drug release rate57. A novel self-assembled amphiphilic PCL grafted 
PVA copolymer (PCL-g-PVA) has been formulated by a dialysis method for the controlled 
release of PTX and DOX (up to 20 and 15 days, respectively)29. 
It has also been suggested the preparation of PCL nanoparticles surface-coated with 
chitosan for the delivery of Mitomycin C (MMC). The pharmacokinetic profile of the drug 
was improved by its vehiculization into the polymeric nanoparticles. Furthermore, this MMC-
loaded nanoplatform showed a very efficient anti-tumor activity against a MB49 bladder 
carcinoma cell line30. 
Finally, PCL nanoparticles have also been used for gene delivery in cancer treatment. As 
an example, specific small interfering RNA (siRNAs) that target the estrogen receptor alpha 
(ERα) were encapsulated in PEGylated poly(ε-caprolactone-malic acid) (PEG-PCL/MA) 
nanocapsules (diameter: 100 – 200 nm, loading effici ncy ≈ 70 %), as a novel strategy in the 
treatment of hormone-dependent breast cancers. Fluorescence quenching assays confirmed 
the incorporation of siRNA into the nanocapsule core. A persistent loss of ERα (90 % over 5 
days) was observed in MCF-7 human breast cancer cells that were treated with this 
formulation. Furthermore, the intravenous injection f these nanocapsules into estradiol-
stimulated MCF-7 cell xenografts led to a significant decrease in tumor growth and a decrease 
in ERα expression in tumor cells58. In this way, several studies have pointed out the benefits 
of the combination of nanotherapeutic strategies including both gene silencing and drug 
delivery, especially in the treatment of refractory tumors. As an example, PEO-PCL 
nanoparticles were formulated to efficiently encapsulate MDR-1 silencing siRNA and PTX. 
Upon administration in MDR SKOV3TR human ovarian adenocarcinoma cells, siRNA-
mediated MDR-1 gene silencing was evident at a 100 nM dose. The combination of MDR-1 
gene silencing and nanoparticle-mediated delivery significantly influenced the cytotoxic 
activity of PTX in SKOV3TR cells. The enhancement in cytotoxicity (action close to what was 
observed in drug sensitive SKOV3 cells) was attribued to an increase in the intracellular drug 
accumulation upon MDR-1 gene silencing, leading to an apoptotic cell-kill effect59. 
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CONCLUSIONS 
Poly(ε-caprolactone) colloids loaded with chemotherapy agents have shown in principle 
very promising results against cancer. However, in order to achieve an optimal anti-tumor 
activity, it is needed the control of the biological f te of these drug delivery systems. 
Therefore, significant engineering efforts should be focused on the development of poly(ε-
caprolactone) nanocarriers able to respond to physiological or physical stimuli, as well as to 
enhance the delivery of drugs to targeted cancers. Thi  involves the need for an effective drug 
transport into tumors, an adequate control of the biochemical factors regulating drug release 
and the maintenance of drug levels over the minimum cytotoxic concentration. Hence, the 
future of poly(ε-caprolactone) nanoplatforms in anticancer therapy will depend on advances 
in the design and nanoengineering of such kind of colloids, as well as on an improved 
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